高血压影响着全球许多人，是肾病、中风、缺血性心脏病和其他血管疾病的常见原因。尽管许多抗高血压药物在临床实践中使用安全有效，但仅通过降低血压（BP）来控制高血压并发症可能具有挑战性。 α-Mangostin 是从 Garcinia mangostana L. 果皮中提取的一种氧杂蒽酮分子，具有抗肿瘤、抗高尿酸血症和抗炎等多种有益作用。然而，α-山竹素对高血压的影响仍不清楚。在这项研究中，我们观察到 α-Mangostin 显着降低自发性高血压大鼠 (SHR) 的收缩压和舒张压，这可能是通过下调血管紧张素 II (Ang II) 来实现的。我们还发现了高血压肾病的早期标志物，包括尿 N-乙酰基-β-D-氨基葡萄糖苷酶 (NAG) 和 β2-微球蛋白 (β2-MG)，这些标志物通过 α-Mangostin 治疗而减少。机制研究表明，α-Mangostin 可能通过下调 TGF-β 信号通路来抑制肾小管上皮间质转化 (EMT)，从而可能为高血压和高血压肾病提供新的治疗方法。© 作者。

Hypertension affects a large number of individuals globally and is a common cause of nephropathy, stroke, ischaemic heart disease and other vascular diseases. While many anti-hypertensive medications are used safely and effectively in clinic practice, controlling hypertensive complications solely by reducing blood pressure (BP) can be challenging. α-Mangostin, a xanthone molecule extracted from the pericarp of Garcinia mangostana L., has shown various beneficial effects such as anti-tumor, anti-hyperuricemia, and anti-inflammatory properties. However, the effects of α-Mangostin on hypertension remain unknown. In this study, we observed that α-Mangostin significantly decreased systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR), possibly through the down-regulation of angiotensin II (Ang II). We also identified early markers of hypertensive nephropathy, including urinary N-acetyl-β-D-glucosaminidase (NAG) and β2-microglobulin (β2-MG), which were reduced by α-Mangostin treatment. Mechanistic studies suggested that α-Mangostin may inhibit renal tubular epithelial-to-mesenchymal transformation (EMT) by down-regulating the TGF-β signaling pathway, thus potentially offering a new therapeutic approach for hypertension and hypertensive nephropathy.© The author(s).